BridgeMD
New treatment option for Extensive-stage Small Cell Lung Cancer
Official title Radiotherapy to All Residual Lesions After Chemoimmunotherapy
ClinicalTrials.gov ID: NCT06479473
What this study is testing
What is Chemoimmunotherapy?
Chemoimmunotherapy is an investigational medicine, being studied as a potential treatment for extensive-stage small cell lung cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Extensive-stage small-cell lung cancer is a lethal malignancy with an extremely poor prognosis. First-line chemotherapy could only achieve an overall survival of approximately 10 months.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- 18-70 years old;
- ECOG 0-1;
- Adequate organ function to tolerate chemotherapy, immunotherapy and radiotherapy;
- Small-cell lung cancer;
- Extensive stage confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT;
You likely can't join if
- Younger than 18 years old or older than 70 years old;
- ECOG\>1;
- Inadequate organ function to tolerate chemotherapy, immunotherapy and radiotherapy;
- Non-small cell lung cancer and other neuroendocrine carcinoma including typical or atypical carcinoid, large-cell neuroendocrine carcinoma;
- Limited stage confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT;
- No signature of inform consent.
See the full eligibility criteria
- 18-70 years old;
- ECOG 0-1;
- Adequate organ function to tolerate chemotherapy, immunotherapy and radiotherapy;
- Small-cell lung cancer;
- Extensive stage confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT;
- Signature of inform consent.
- Younger than 18 years old or older than 70 years old;
- ECOG\>1;
- Inadequate organ function to tolerate chemotherapy, immunotherapy and radiotherapy;
- Non-small cell lung cancer and other neuroendocrine carcinoma including typical or atypical carcinoid, large-cell neuroendocrine carcinoma;
- Limited stage confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT;
- No signature of inform consent.
The study team makes the final eligibility decision.
Where it's taking place
- Hefei, Anhui, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hefei, Anhui, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.